APA (7th ed.) Citation

Wegerif, E. C., Ünlü, Ç., Generaal, M. I., van den Bor, R. M., van de Ven, P. M., Bots, M. L., & de Borst, G. J. (2024). Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty (CLEAR-PATH). The American heart journal, 273, 121-129. https://doi.org/10.1016/j.ahj.2024.04.001

Chicago Style (17th ed.) Citation

Wegerif, Emilien C.J., Çağdaş Ünlü, Manon I. Generaal, Rutger M. van den Bor, Peter M. van de Ven, Michiel L. Bots, and Gert J. de Borst. "Rationale and Design for the Randomized Placebo-controlled Double-blind Trial Studying the Effect of Single Antiplatelet Therapy (clopidogrel) Versus Dual Antiplatelet Therapy (clopidogrel/acetylsalicylic Acid) on the Occurrence of Atherothrombotic Events Following Lower Extremity Peripheral Transluminal Angioplasty (CLEAR-PATH)." The American Heart Journal 273 (2024): 121-129. https://doi.org/10.1016/j.ahj.2024.04.001.

MLA (9th ed.) Citation

Wegerif, Emilien C.J., et al. "Rationale and Design for the Randomized Placebo-controlled Double-blind Trial Studying the Effect of Single Antiplatelet Therapy (clopidogrel) Versus Dual Antiplatelet Therapy (clopidogrel/acetylsalicylic Acid) on the Occurrence of Atherothrombotic Events Following Lower Extremity Peripheral Transluminal Angioplasty (CLEAR-PATH)." The American Heart Journal, vol. 273, 2024, pp. 121-129, https://doi.org/10.1016/j.ahj.2024.04.001.